Diffuse large B-cell lymphoma
LH Sehn, G Salles - New England Journal of Medicine, 2021 - Mass Medical Soc
Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
Y Liu, SK Barta - American journal of hematology, 2019 - Wiley Online Library
Abstract Disease Overview Diffuse large B‐cell lymphoma (DLBCL) is the most common
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …
type of aggressive non‐Hodgkin lymphoma originating from the germinal center, and it …
[HTML][HTML] Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
SS Neelapu, M Dickinson, J Munoz, ML Ulrickson… - Nature medicine, 2022 - nature.com
High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line
chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study …
chemoimmunotherapy. In the phase 2, multicenter, single-arm ZUMA-12 study …
Genomic profiling for clinical decision making in lymphoid neoplasms
L De Leval, AA Alizadeh, PL Bergsagel… - Blood, The Journal …, 2022 - ashpublications.org
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Diffuse large B-cell lymphoma
S Li, KH Young, LJ Medeiros - Pathology, 2018 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …
worldwide, representing approximately 30–40% of all cases in different geographic regions …
Non-hodgkin lymphoma
JO Armitage, RD Gascoyne, MA Lunning, F Cavalli - The lancet, 2017 - thelancet.com
Lymphomas can affect any organ in the body, present with a wide range of symptoms, and
be seen by primary care physicians and physicians from most specialties. They are …
be seen by primary care physicians and physicians from most specialties. They are …
[HTML][HTML] Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised …
A Davies, TE Cummin, S Barrans, T Maishman… - The Lancet …, 2019 - thelancet.com
Background Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified
using gene-expression analysis to determine their cell of origin, corresponding to germinal …
using gene-expression analysis to determine their cell of origin, corresponding to germinal …
CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP
N Schmitz, S Zeynalova, M Nickelsen… - Journal of Clinical …, 2016 - ascopubs.org
Purpose To develop and validate a risk score for relapse in the CNS in patients with diffuse
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker …
A Rosenwald, S Bens, R Advani, S Barrans… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-
cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies …
cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies …
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
LH Sehn, RD Gascoyne - Blood, The Journal of the American …, 2015 - ashpublications.org
Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …
with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R …